Healius Limited (ASX:HLS)

Market Cap	235.99M -63.3%
Revenue (ttm)	1.37B +6.0%
Net Income	-168.80M
EPS	-0.23
Shares Out	726.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.41 (127.08%)
Ex-Dividend Date	May 9, 2025

Volume	2,174,400
Open	0.3250
Previous Close	0.3200
Day's Range	0.3150 - 0.3250
52-Week Range	0.3050 - 1.0700
Beta	0.27
Analysts	Sell
Price Target	0.51 (+56.92%)
Earnings Date	Aug 19, 2026

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 8,224
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for HLS stock is "Sell." The 12-month stock price target is $0.51, which is an increase of 56.92% from the latest price.

Price Target

$0.51

(56.92% upside)

Analyst Consensus: Sell